Genecast MRD MinerVa is our proprietary MRD detection reagent kit utilizing capture-based targeted cfDNA NGS sequencing, to be used in the testing process of our NGS-based MRD test and provides postoperative prognosis and recurrence risk assessment for patients with NSCLC, CRC, breast and other cancer types.

Genecast MinerVa MRD is an NGS-based large-panel MRD detection test, developed specifically for postoperative risk assessment, recurrence monitoring, and adjuvant therapy evaluation in NSCLC. It employs a tumor-informed strategy using a fixed panel of 769 cancer-related genes. By sequencing both the resected tumor tissue and ctDNA from blood samples, Genecast MinerVa MRD identifies patient-specific mutations and tracks them longitudinally to detect the presence of MRD with exceptional sensitivity and specificity.

Genecast MinerVa MRD integrates high-throughput sequencing with our proprietary bioinformatics pipeline to enable comprehensive mutation tracking. Its panel design emphasizes both breadth and depth, covering key oncogenic pathways while intensifying coverage at known driver and resistance hotspots through an in-house weighting algorithm. This design enhances the detection of low-frequency clonal variants critical to MRD assessment. The system achieves an analytical LoD as low as 0.008% and demonstrated a 100% detection rate at a ctDNA fraction of 0.01% in analytical studies, while maintaining specificity averaged 99.5% by incorporating a background error model built from thousands of tumor-negative plasma samples.

The performance and clinical value of Genecast MinerVa MRD have been extensively validated through the LUNGCA study, the largest international prospective, multi-center cohort focused on MRD detection in resected NSCLC. Involving 330 patients and over 2,500 serial plasma samples collected within three years post-surgery, the study achieved a median follow-up time of 51.4 months and an average of more than 10 plasma samples per patient. Findings from LUNGCA demonstrated that MRD positivity after surgery strongly correlates with recurrence risk and provides timely guidance on the need for adjuvant therapy. Importantly, patients with targetable mutations benefited significantly from TKI therapy, which led to improved recurrence-free survival and more effective ctDNA clearance than chemotherapy. Moreover, ctDNA-negative status following recurrence was associated with favorable long-term outcomes, offering prognostic value for second-line treatment planning.

By combining comprehensive panel design, highly sensitive detection algorithms, and robust clinical evidence, Genecast MinerVa MRD enables dynamic and personalized postsurgical monitoring. It supports key clinical decisions including recurrence surveillance, adjuvant therapy selection, treatment efficacy assessment, and survival prediction, paving the way for more precise and proactive oncology care. 

We obtained CE marking for Genecast MRD MinerVa for solid tumors in June 2025.